AI Article Synopsis

  • Lyme disease cases are rising, prompting the development of new vaccine candidates, but understanding public acceptance is crucial before market release.
  • A survey conducted in June-July 2018 across several states found that 64% of respondents were willing to get vaccinated, while 30% were uncertain, and 7% were unwilling.
  • Factors influencing vaccine hesitancy included being non-White, having less education, safety concerns, low confidence in vaccines, and a low perceived risk of Lyme disease.

Article Abstract

Background: Lyme disease incidence is increasing, despite current prevention options. New Lyme disease vaccine candidates are in development, however, investigation of the acceptability of a Lyme disease vaccine among potential consumers is needed prior to any vaccine coming to market. We conducted a population-based, cross-sectional study to estimate willingness to receive a potential Lyme disease vaccine and factors associated with willingness.

Methods: The web-based survey was administered to a random sample of Connecticut, Maryland, Minnesota, and New York residents June-July 2018. Survey-weighted descriptive statistics were conducted to estimate the proportion willing to receive a potential Lyme disease vaccine. Multivariable multinomial logistic regression models were used to quantify the association of sociodemographic characteristics and Lyme disease vaccine attitudes with willingness to be vaccinated.

Results: Surveys were completed by 3313 respondents (6% response rate). We estimated that 64% of residents were willing to receive a Lyme disease vaccine, while 30% were uncertain and 7% were unwilling. Compared to those who were willing, those who were uncertain were more likely to be parents, adults 45-65 years old, non-White, have less than a bachelor's degree, or have safety concerns about a potential Lyme disease vaccine. Those who were unwilling were also more likely to be non-White, have less than a bachelor's degree, or have safety concerns about a potential Lyme disease vaccine. In addition, the unwilling had low confidence in vaccines in general, had low perceived risk of contracting Lyme disease, and said they would not be influenced by a positive recommendation from a healthcare provider.

Discussion: Overall, willingness to receive a Lyme disease vaccine was high. Effective communication by clinicians regarding safety and other vaccine parameters to those groups who are uncertain will be critical for increasing vaccine uptake and reducing Lyme disease incidence.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11705932PMC
http://dx.doi.org/10.1016/j.vaccine.2021.11.065DOI Listing

Publication Analysis

Top Keywords

lyme disease
52
disease vaccine
40
potential lyme
20
lyme
13
disease
13
vaccine
13
population-based cross-sectional
8
disease incidence
8
willingness receive
8
receive potential
8

Similar Publications

As per published literature, the tick is the primary Lyme disease vector in British Columbia (BC), while the tick species is the dominant vector on the East Coast of Canada, with no . presence seen in BC. However, a recent publication reported presence of in BC which initiated this study to determine the accuracy of the microscopic identification of ticks received in the BC Centre for Disease Control (BCCDC) Public Health Laboratory and compare morphologic methods to molecular methods.

View Article and Find Full Text PDF

Intermittent High-Degree AV Block, Rash, and Facial Droop with Negative Lyme PCR.

J Emerg Med

August 2024

Department of Emergency Medicine, University of Kentucky, Lexington, Kentucky.

Background: Lyme disease is the most common tick-borne illness in the United States, and cases of Lyme disease have nearly doubled since the early 2000s. Symptoms and presentation vary based on severity of illness, with more serious complications of disease consisting of neurologic and cardiac dysfunction. Testing is often unreliable, which can lead to delayed diagnosis and management.

View Article and Find Full Text PDF

Procalcitonin-guided duration of antibiotic treatment in children hospitalised with confirmed or suspected bacterial infection in the UK (BATCH): a pragmatic, multicentre, open-label, two-arm, individually randomised, controlled trial.

Lancet Child Adolesc Health

January 2025

Department of Infectious Diseases, Alder Hey Children's NHS Foundation Trust, Liverpool, UK; Department of Clinical Infection, Microbiology, and Immunology, Institute of Infection, Veterinary, and Ecological Sciences, University of Liverpool, Liverpool, UK. Electronic address:

Background: Procalcitonin is a rapid response biomarker specific for bacterial infection, which is not routinely used in the UK National Health Service. We aimed to assess whether using a procalcitonin-guided algorithm would safely reduce the duration of antibiotic therapy compared with usual care, in which C-reactive protein is the commonly used biomarker.

Methods: The BATCH trial was a pragmatic, multicentre, open-label, parallel, two-arm, individually randomised, controlled trial conducted in 15 hospitals in England and Wales.

View Article and Find Full Text PDF

Molecular Identification of Species in Ticks Infesting Hedgehogs ( and ) in North-Western Poland.

Int J Mol Sci

December 2024

Department of Genetics and Genomics, Institute of Biology, University of Szczecin, Wąska 13, 71-415 Szczecin, Poland.

The western European hedgehog () and the northern white-breasted hedgehog () are natural hosts of the tick , the vector of tick-borne pathogens such as the bacteria responsible for Lyme disease. The aim of this study was to identify these pathogens in ticks collected from hedgehogs in northwestern Poland and to assess their genetic diversity by molecular analysis of the detected pathogens based on the gene and the intergenic spacer. Among 101 hedgehogs examined, 737 ticks were found on 56 (55.

View Article and Find Full Text PDF

A novel panel of peptide for serological identification of Borrelia burgdoferi sensu stricto, Borrelia garinii and Borrelia afzelii was developed and assessed in this study. The diagnostic algorithm of the novel test was initially trained testing 10 US human sera including 3 early-stage and 3 late-stage Lyme disease positive sera, 2 sera positive for Babesia and 2 sera positive for Syphilis, all purchased from a private biorepository. Findings were then corroborated testing (a) 33 additional EU follow-up positive sera from seroconverted patients bitten by ticks that tested positive for B.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!